|
Session 96
Poster Abstracts
Clinical Pharmacology of Non-Nucleoside Reverse Transcriptase Inhibitors
Tuesday, 1:30 - 3:30 pm
Poster Hall |
| 571 |
Multilocus Gene-Gene Interactions May Predict Efavirenz Pharmacokinetics and Treatment Response: Analysis NWCS 213 of ACTG Study 384
Alison Motsinger*1, M Ritchie1, R Shafer2, G Robbins3, G Morse4, G Wilkinson1, D Clifford5, R D’aquila1, R Kim1, and D Haas1
1Vanderbilt Univ Sch of Med, Nashville, TN, US; 2Stanford Univ, CA, US; 3Harvard Med Sch, Boston, MA, USA; 4State Univ of New York, Buffalo, US; and 5Washington Univ, St Louis, MO, US |
572
 |
Genetic Variability of CYP2B6 in Individuals with Extremely High Efavirenz Plasma Concentrations
Margalida Rotger*1,2, S Colombo2, M Cavassini2, H Furrer3, L Elzi4, H Günthard5, L Décosterd2, A Telenti1,2, and Swiss HIV Cohort Study
1Inst of Microbiology, Univ of Lausanne, Switzerland; 2Ctr Univ Hosp Vaudois, Lausanne, Switzerland; 3Berne Univ Hosp, Switzerland; 4Basel Univ Hosp, Switzerland; and 5Univ Hosp, Zürich, Switzerland |
573
|
The Steady-state Pharmacokinetics of Efavirenz and Lopinavir/Ritonavir in HIV-infected Persons Requiring Hemodialysis: AIDS Clinical Trials Group Study A5177
Samir Gupta*1, S Rosenkranz2, Y Segal2, S Koletar3, M Basar4, L Szczech5, V Amorosa6, S Hall1, and AIDS Clin Trials Group 5177 Protocol Team
1Indiana Univ Sch of Med, Indianapolis, US; 2Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Ohio State Univ, Columbus, US; 4Frontier Sci & Tech Res Fndn, Amherst, NY, US; 5Duke Univ Med Ctr, Durham, NC, US; and 6Univ of Pennsylvania, Philadelphia, US |
| 574 |
Effect of Rifampin Hepatic Induction on Nevirapine Levels in Indian Volunteers
Sanjay Pujari*1,2, V Bele3, K Joshi3, S Sawant4, S Joshi4, J Nadler2, J Sinnott2, E Naik2, D Dabhade5, and L Menzes2
1Ruby Hall Clin, Pune, India; 2Univ of South Florida, Tampa, US; 3Han UL Medizin, Pune, India; 4Accutest Res Labs, Dayton, NJ, US; and 5Medicare Lab, Pune, India |
575a
|
A 2-Way Pharmacokinetic Interaction between Efavirenz and Carbamazepine
Sanjeev Kaul*, P Ji, J Xie, F Johnson, S Unger, and S Rahim
Bristol-Myers Squibb, Princeton, NJ, US |
575b
|
Pharmacokinetics and Safety of Adding TMC125 to Stable Regimens of Saquinavir, Lopinavir, Ritonavir, and NRTI in HIV+ Adults
Marianne Harris*1, C Zala2, S Ramirez1, B Woodfall3, M Peeters3, M Scholler3, R Hoetelmans3, and J Montaner1
1BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada; 2Fndn Hosp, Univ of Buenos Aires, Argentina; and 3Tibotec Pharm, Mechelen, Belgium |
| 575c |
Pharmacokinetics and ART Response to TMC114/r and TMC125 Combination in Patients with High-level Viral Resistance.
Marta Boffito*1, A Winston1, C Fletcher1, A Pozniak1, M Nelson1, G Moyle1, I Tolowinska1, R Hoetelmans2, D Miralles2, and B Gazzard1
1Chelsea and Westminster Hosp, London, UK and 2Tibotec BVBA, Mechelen, Belgium. |
|
